cyclopropanesulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide | 1292258-77-5

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: cyclopropanesulfonic acid (3-fluoro-4-{6-methoxy-7-[3-(3-methyl-piperidin-1-yl)-propoxy]-quinolin-4-yloxy}-phenyl)-amide
• 英文别名: N-[3-fluoro-4-[6-methoxy-7-[3-(3-methylpiperidin-1-yl)propoxy]quinolin-4-yl]oxyphenyl]cyclopropanesulfonamide
• CAS: 1292258-77-5
• 化学式: C₂₈H₃₄FN₃O₅S
• 分子量: 543.659
• InChiKey: SBNALRVEVFOFLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  38
• 可旋转键数：
  11
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  98.4
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• [EN] ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE L'ECTONUCLÉOTIDE PYROPHOSPHATASE-PHOSPHODIESTÉRASE (ENPP-1) ET UTILISATIONS DE CES DERNIERS
  申请人：MAVUPHARMA INC

  公开号：WO2019046778A1

  公开（公告）日：2019-03-07

  Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.

  本文揭示了一种增强和促进体内I型干扰素产生的方法和化合物。在某些实施例中，本文所披露的化合物是ENPP-1抑制剂，药物组合物，以及用于治疗癌症或病毒感染的方法。
• [EN] QUINOLINYLOXYPHENYLSULFONAMIDES<br/>[FR] QUINOLINYLOXYPHÉNYLSULFONAMIDES
  申请人：MAX PLANCK GESELLSCHAFT

  公开号：WO2011045084A1

  公开（公告）日：2011-04-21

  The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.

  本发明涉及喹啉氧基苯磺酰胺及其立体异构体形式、溶剂化物、水合物和/或这些喹啉氧基苯磺酰胺化合物的药学上可接受的盐，以及含有至少一种这些化合物和至少一种药学上可接受的载体、赋形剂和/或稀释剂的制剂。所述喹啉氧基苯磺酰胺对于预防、治疗和/或后治疗增生性疾病，如癌症、肿瘤，特别是癌症转移，具有有用的作用。
• Quinolinyloxyphenylsulfonamides
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2311809A1

  公开（公告）日：2011-04-20

  The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.

  本发明涉及喹啉氧基苯磺酰胺及其立体异构体、前药、溶剂化物、水合物和/或药学上可接受的盐，以及包含至少一种这些化合物和至少一种药学上可接受的载体、赋形剂和/或稀释剂的制药组合物。所述喹啉氧基苯磺酰胺对于预防、治疗和/或后治疗增殖过度的疾病，如癌症、肿瘤，尤其是癌症转移，是有用的。
• QUINOLINYLOXYPHENYLSULFONAMIDES
  申请人：Ullrich Axel

  公开号：US20120277231A1

  公开（公告）日：2012-11-01

  The present invention relates to quinolinyloxyphenylsulfonamides and stereoisomeric forms, solvates, hydrates and/or pharmaceutically acceptable salts of these quinolinyloxyphenylsulfonamide compounds as well as pharmaceutical compositions containing at least one of these compounds together with at least one pharmaceutically acceptable carrier, excipient and/or diluent. Said quinolinyloxyphenylsulfonamides are useful for prophylaxsis, treatment and/or after-treatment of hyperproliferative disorders, such as cancer, tumors and particularly cancer metastases.

  本发明涉及喹啉氧基苯磺酰胺及其立体异构体、溶剂化物、水合物和/或药学上可接受的盐，以及至少包含其中一种化合物和至少一种药学上可接受的载体、赋形剂和/或稀释剂的制药组合物。所述喹啉氧基苯磺酰胺对于预防、治疗和/或后治疗增生性疾病，如癌症、肿瘤和特别是癌症转移，具有有用的作用。
• ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF
  申请人：AbbVie Inc.

  公开号：US20200291024A1

  公开（公告）日：2020-09-17

  Disclosed herein are methods and compounds of augmenting and enhancing the production of type I IFNs in vivo. In some embodiments, the compounds disclosed herein are ENPP-1 inhibitors, pharmaceutical compositions, and methods for the treatment of cancer or a viral infection.